南京英派药业股份有限公司（股票简称：英派药业-B，股票代码：07630）9月7日发布自愿公告称，公司H股已被上海证券交易所及深圳证券交易所纳入沪港通及深港通合资格证券名单，生效日期为2026年9月7日。 \n\n公告指出，H股被纳入相关名单后，中国内地合资格投资者可通过沪股通或深股通渠道直接买卖英派药业-B的H股。公司认为，这一安排有望扩大其投资者基础，并提升H股交易流动性。 \n\n沪港通及深港通是上海证券交易所、深圳证券交易所与香港联合交易所有限公司之间的股票市场交易互联互通机制。该机制允许内地与香港的投资者通过当地证券公司或经纪机构，跨境买卖在对方交易所上市的合资格股票。 \n\n公司提醒股东及潜在投资者在买卖公司股份时应保持审慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.